VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer-Reference-Cited by-同舟云学术

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer

Published:2017-03-27 Issue:5 Volume:23 Page:551-555
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Gao Jianjun,Ward John F,Pettaway Curtis A,Shi Lewis Z,Subudhi Sumit K,Vence Luis M,Zhao Hao,Chen Jianfeng,Chen Hong,Efstathiou Eleni,Troncoso Patricia,Allison James P,Logothetis Christopher J,Wistuba Ignacio I,Sepulveda Manuel A,Sun Jingjing,Wargo Jennifer,Blando Jorge,Sharma Padmanee

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4308.pdf

Reference20 articles.

1. Sharma, P. & Allison, J.P. Cell 161, 205–214 (2015).

2. Sharma, P. & Allison, J.P. Science 348, 56–61 (2015).

3. Kwon, E.D. et al. Lancet Oncol. 15, 700–712 (2014).

4. Topalian, S.L. et al. N. Engl. J. Med. 366, 2443–2454 (2012).

5. Subudhi, S.K. et al. Proc. Natl. Acad. Sci. USA 113, 11919–11924 (2016).

Cited by 486 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

2. Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial;2024-09-11

3. TET3 is expressed in prostate cancer tumor-associated macrophages and is associated with anti-androgen resistance;Clinical and Translational Oncology;2024-09-06

4. A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma;iScience;2024-09

5. Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09